Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath-based T-cell Depleted Allo-SCT for Hematologic Malignancies
NCT00683046Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Nov 2001
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in hematologic malignancy, sponsored by University of Chicago. Started Nov 2001; status: completed.
02
Drugs
alemtuzumab
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT00683046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00683046.